10 Funding Applications: A Phase 1, First-in Human, PDAC Clinical Trial Protocol of a LLM-Directed Robotic Whipple with Daraxonrasib (RMC-6236)

In July 2026 the White House asked the federal research portfolio, approximately $200 billion annually, to prioritise the individual scientist over legacy institutions. This paper reports what happens when one unaffiliated scientist takes that literally and writes ten funding applications for the same Phase 1 pancreatic cancer trial, each addressing the mechanism its recipient runs. The trial is constant across all ten: an open-label, single-arm, 3+3 escalation of perioperative daraxonrasib (RMC-6236) in up to 18 participants with resectable or borderline-resectable KRAS G12-mutated pancreatic ductal adenocarcinoma, performed as a staged eight-arm robotic pancreaticoduodenectomy with an on-premises language model confined to advisory output. Five lead with the operation and five with the drug; both sets describe the same hybrid procedure. UC San Diego Moores Cancer Center is named in all ten as the intended partner of choice, at the feasibility stage only, and described nowhere as a partner, sponsor, site, or endorser. The evidence is stated with its limits attached. An August 2025 quantitative systems pharmacology simulation returned median overall survival of 12.8 months against 5.4 for chemotherapy; in May 2026 RASolute 302 reported 13.2 against 6.6 months in the RAS G12 metastatic population. That proximity is chronology, not validation, and neither result speaks to resectable setting, which is what trial would measure.